Annual report pursuant to Section 13 and 15(d)

Licensing and Other Arrangements - Novartis International (Details)

v3.20.4
Licensing and Other Arrangements - Novartis International (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Oct. 21, 2020
USD ($)
Sep. 30, 2015
item
Sep. 30, 2015
Dec. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2015
USD ($)
Licensing and other arrangements                
Revenue from contracts with customers         $ 27,941 $ 17,276    
Novartis Note                
Licensing and other arrangements                
Reduction in debt obligation $ 7,300              
Novartis International | License Agreement                
Licensing and other arrangements                
Agreement termination prior written notice period   180 days            
Number of performance obligations | item   1            
Cash payment received 17,700             $ 37,000
Revenue from contracts with customers $ 25,000     $ 25,000 25,000 0 $ 10,000 $ 37,000
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones         470,000      
Royalty payment period     10 years          
Contract assets       0 0 0    
Contract liabilities       0 0 0    
Capitalized contract costs       $ 0 $ 0 $ 0